JP7828949B2 - 吸入投与のための併用療法 - Google Patents

吸入投与のための併用療法

Info

Publication number
JP7828949B2
JP7828949B2 JP2023506220A JP2023506220A JP7828949B2 JP 7828949 B2 JP7828949 B2 JP 7828949B2 JP 2023506220 A JP2023506220 A JP 2023506220A JP 2023506220 A JP2023506220 A JP 2023506220A JP 7828949 B2 JP7828949 B2 JP 7828949B2
Authority
JP
Japan
Prior art keywords
solution composition
pharmaceutical solution
composition according
ethanol
soft mist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023506220A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540171A5 (cg-RX-API-DMAC7.html
JP2023540171A (ja
Inventor
オレジャナ,アレハンドロ ニエト
プエルトリャノ,マリア マエソ
ベニテス,ラウラ アンドラデ
Original Assignee
ケモ リサーチ, エス.エル.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72039503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7828949(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ケモ リサーチ, エス.エル. filed Critical ケモ リサーチ, エス.エル.
Publication of JP2023540171A publication Critical patent/JP2023540171A/ja
Publication of JP2023540171A5 publication Critical patent/JP2023540171A5/ja
Application granted granted Critical
Publication of JP7828949B2 publication Critical patent/JP7828949B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023506220A 2020-07-31 2021-07-30 吸入投与のための併用療法 Active JP7828949B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382710.0 2020-07-31
EP20382710 2020-07-31
PCT/EP2021/071369 WO2022023515A1 (en) 2020-07-31 2021-07-30 Combination therapy for inhalation administration

Publications (3)

Publication Number Publication Date
JP2023540171A JP2023540171A (ja) 2023-09-22
JP2023540171A5 JP2023540171A5 (cg-RX-API-DMAC7.html) 2025-11-27
JP7828949B2 true JP7828949B2 (ja) 2026-03-12

Family

ID=72039503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023506220A Active JP7828949B2 (ja) 2020-07-31 2021-07-30 吸入投与のための併用療法

Country Status (13)

Country Link
US (1) US20230270754A1 (cg-RX-API-DMAC7.html)
EP (1) EP4188327B1 (cg-RX-API-DMAC7.html)
JP (1) JP7828949B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230052903A (cg-RX-API-DMAC7.html)
CN (1) CN115989032A (cg-RX-API-DMAC7.html)
AU (1) AU2021314977B2 (cg-RX-API-DMAC7.html)
BR (1) BR112023001689A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186956A1 (cg-RX-API-DMAC7.html)
ES (1) ES3037198T3 (cg-RX-API-DMAC7.html)
FI (1) FI4188327T3 (cg-RX-API-DMAC7.html)
MX (1) MX2023001201A (cg-RX-API-DMAC7.html)
PL (1) PL4188327T3 (cg-RX-API-DMAC7.html)
WO (1) WO2022023515A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188327B1 (en) 2020-07-31 2025-05-28 Chemo Research, S.L. Combination therapy for inhalation administration
WO2026057872A1 (en) * 2024-09-16 2026-03-19 Invox Belgium Nv Inhalable compositions
CN121714579A (zh) * 2026-02-25 2026-03-24 上海臣邦医药科技股份有限公司 一种三联复方吸入制剂的药物组合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193213A1 (en) 2014-06-18 2015-12-23 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
WO2017089404A1 (en) 2015-11-25 2017-06-01 Jagotec Ag Pharmaceutical composition
JP2019528316A (ja) 2016-08-17 2019-10-10 チエシ ファーマシューティシ エス.ピー.エー. Copdに対する組合せ療法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851317A (en) 1987-11-04 1989-07-25 E. I. Du Pont De Nemours And Company Laminar flow toning station having conductive and nonconductive elements therein
BR9609307B1 (pt) 1995-06-27 2010-03-09 preparação farmacêutica para produção de aerossóis inaláveis isentos de propelentes para administração nos pulmões, bem como aerossol compreendendo a mesma.
DE19536902A1 (de) 1995-10-04 1997-04-10 Boehringer Ingelheim Int Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
DK1121112T3 (da) * 1998-10-17 2002-09-16 Boehringer Ingelheim Pharma Lagringsdygtigt koncentrat af aktivt stof med formoterol
EE05167B1 (et) 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
CA2733294C (en) 2000-10-31 2011-12-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination of a tiotropium salt and ciclesonide
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1879571A1 (de) 2005-04-23 2008-01-23 Boehringer Ingelheim International GmbH Arzneimittelkombination für die inhalation enthaltend neben einem anticholinergikum ein betamimetikum und ein steroid
ITMI20051999A1 (it) * 2005-10-21 2007-04-22 Eratech S R L Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20070293460A1 (en) 2005-10-31 2007-12-20 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
US20070098644A1 (en) 2005-10-31 2007-05-03 Richie's Pharmacy And Medical Supply, Incorporated Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
DE102006023756A1 (de) 2006-05-20 2007-11-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanolhaltige Aerosolformulierung für die Inhalation
UY30542A1 (es) 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
HRP20140582T4 (hr) 2009-12-23 2023-06-09 Chiesi Farmaceutici S.P.A. Kombinacijska terapija za copd
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
SG181870A1 (en) 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
US20120220557A1 (en) 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
HRP20181980T1 (hr) 2012-12-21 2019-01-25 Boehringer Ingelheim Vetmedica Gmbh Ciklezonid za liječenje dišnih puteva kod konja
JP6534397B2 (ja) 2013-12-30 2019-06-26 シエシー ファルマセウティチィ ソシエタ ペル アチオニ グリコピロニウム臭化物およびホルモテロールの組合せの安定な加圧エアゾール溶液組成物
AU2014375301C1 (en) * 2013-12-30 2026-02-19 Chiesi Farmaceutici S.P.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
WO2020167893A1 (en) 2019-02-13 2020-08-20 Molecular Infusions, Llc Methods for non-irritating pulmonary administration of cannabinoids using soft mist inhalers
EP4188327B1 (en) 2020-07-31 2025-05-28 Chemo Research, S.L. Combination therapy for inhalation administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015193213A1 (en) 2014-06-18 2015-12-23 Boehringer Ingelheim Vetmedica Gmbh Muscarinic antagonists and combinations thereof for the treatment of airway disease in horses
WO2017089404A1 (en) 2015-11-25 2017-06-01 Jagotec Ag Pharmaceutical composition
JP2019528316A (ja) 2016-08-17 2019-10-10 チエシ ファーマシューティシ エス.ピー.エー. Copdに対する組合せ療法

Also Published As

Publication number Publication date
CA3186956A1 (en) 2022-02-03
PL4188327T3 (pl) 2025-09-01
US20230270754A1 (en) 2023-08-31
MX2023001201A (es) 2023-05-03
FI4188327T3 (fi) 2025-07-25
BR112023001689A2 (pt) 2023-05-02
WO2022023515A1 (en) 2022-02-03
AU2021314977B2 (en) 2025-03-13
JP2023540171A (ja) 2023-09-22
EP4188327B1 (en) 2025-05-28
CN115989032A (zh) 2023-04-18
ES3037198T3 (en) 2025-09-30
AU2021314977A1 (en) 2023-03-02
KR20230052903A (ko) 2023-04-20
EP4188327A1 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
AU2003210370C1 (en) Pressurised metered dose inhalers containing solutions of beta-2 agonists
RU2327450C2 (ru) Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
CN103052378A (zh) 包含磷酸二酯酶抑制剂的药物制剂
JP2009502997A (ja) 噴霧投与用の長時間作用型ベータ2−アゴニストを含む医薬製剤
EP2999460A1 (en) Compositions, methods&systems for respiratory delivery of three or more active agents
AU2021314977B2 (en) Combination therapy for inhalation administration
EP4585215A1 (en) Pharmaceutical composition for inhalation for preventing or treating respiratory disease
EP1415647A1 (en) "Long-acting beta-2 agonists ultrafine formulations"
JP2017515835A (ja) Copdの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ
US9808423B2 (en) Preparation of suspension aerosol formulations
WO2021138386A1 (en) Propellant-free formulation for inhalation
HK1079425B (zh) 福莫特罗超细制剂
HK1118473A (en) Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240603

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250919

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260302

R150 Certificate of patent or registration of utility model

Ref document number: 7828949

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150